6 Grants
2019
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors
LECLERC, ESTELLE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM109024-04-5957), $202,810USD, 2019
2018
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors
LECLERC, ESTELLE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM109024-03-5957), $172,921USD, 2018
2017
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors
LECLERC, ESTELLE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM109024-02-5957), $212,747USD, 2017
2016
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors
LECLERC, ESTELLE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 1P20GM109024-01A1-5957), $232,725USD, 03/01/2016 -- 02/28/2021
2012
Targeting RAGE/Abeta interaction with single chain monoclonal antibodies
LECLERC, ESTELLE
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 5R03AG040580-02), $58,835USD, 08/01/2011 -- 07/31/2013
2011
Targeting RAGE/Abeta interaction with single chain monoclonal antibodies
LECLERC, ESTELLE
National Institutes of Health (NIH), National Institute on Aging (NIA) (ID: 1R03AG040580-01), $58,835USD, 08/01/2011 -- 07/31/2013